The Reality: DSIP Is Not an Approved Treatment DSIP is: Not FDA approved Not prescribed in addiction treatment programs Not included in clinical guidelines for opioid use disorder Even though it sounds promising on the surface, theres no strong evidence showing that DSIP can: Reduce cravings Prevent relapse Replace evidence-based treatments Its being discussed far more in online communities and experimental spaces than in real medical settings
HUBERMAN: It's also the case that naturally released growth hormone tends to have positive effects on our mood and overall feelings of wellbeing
Some medical conditions might also cause problems with blood circulation that can lead to numbness, Atherosclerosis: This condition occurs when blood vessels narrow over time due to a buildup of fat and cholesterol, causing reductions in blood flow
PT-141 is unique because it works directly through the nervous system without primarily affecting the vascular system, making it a distinct treatment compared to traditional erectile dysfunction and female sexual dysfunction medications
Stable pentadecapeptide derived from a gastric protein, studied for tendon healing, angiogenesis and gut integrity
Summary: AOD 9604 and retatrutide are both unlicensed investigational compounds in the UK, and there is no clinical evidence or regulatory guidance supporting their combined use